Qiagen NV  

(Public, ETR:QIA)   Watch this stock  
Find more results for QIA
19.57
-0.72 (-3.55%)
Apr 29 - Close
ETR data delayed by 15 mins - Disclaimer
Currency in EUR
Range 19.57 - 20.07
52 week 17.83 - 26.05
Open 20.07
Vol / Avg. 487,975.00/340,625.00
Mkt cap 4.63B
P/E 41.44
Div/yield     -
EPS 0.47
Shares 233.00M
Beta     -
Inst. own     -
Jun 21, 2016
Qiagen NV Annual Shareholders Meeting Add to calendar
May 18, 2016
Qiagen NV at Barclays Americas Select Conference Add to calendar
May 10, 2016
Qiagen NV at Bank of America Merrill Lynch Health Care Conference Add to calendar
May 10, 2016
Qiagen NV at Berenberg Diagnostics Conference Add to calendar
May 4, 2016
Qiagen NV at Deutsche Bank Health Care Conference Add to calendar
Apr 28, 2016
Q1 2016 Qiagen NV Earnings Call
Apr 27, 2016
Q1 2016 Qiagen NV Earnings Release
Mar 16, 2016
Qiagen NV at Barclays Global Healthcare Conference
Mar 1, 2016
Qiagen NV at Morgan Stanley European MedTech & Services Conference
Feb 10, 2016
Qiagen NV at Leerink Partners Global Healthcare Conference
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 13.88% 9.90%
Operating margin 15.61% 13.72%
EBITD margin - 28.66%
Return on average assets 4.65% 2.94%
Return on average equity 7.67% 4.88%
Employees 4,559 -
CDP Score - -

Address

Hulsterweg 82
VENLO, 5912 PL
Netherlands
+31-77-3556600 (Phone)
+31-77-3208409 (Fax)

Website links

Description

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company's bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Officers and directors

Peer M. Schatz Chief Executive Officer, Managing Director
Age: 49
Roland Sackers Chief Financial Officer, Managing Director
Age: 46
Thomas Schweins Senior Vice President - Human Resources, Strategy & Marketing Services
Dietrich Hauffe Senior Vice President - Life Sciences Business Area
Douglas Liu Senior Vice President - Global Operations
Helge Lubenow Senior Vice President - Molecular Diagnostics Business Area
Ulrich Schriek Senior Vice President - Corporate Business Development
Benedikt von Braunmuehl Senior Vice President - Global Commercial Operations
Stephane Bancel Independent Supervisory Director
Age: 42
Werner Brandt Independent Supervisory Director
Age: 62